Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05500170 · ClinicalTrials.gov registry record · NA
Benefits of Nicotinamide Riboside Upon Cognition and Sleep
A NA study of Cognitive Impairment and Sleep Quality, sponsored by State University of New York at Buffalo.
- Recruiting
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 3
- Study locations
NCT05500170: Recruiting NA study of Cognitive Impairment and Sleep Quality, sponsored by State University of New York at Buffalo.
NCT05500170 is a NA study of Cognitive Impairment and Sleep Quality that is actively recruiting participants, run by State University of New York at Buffalo. The registered enrollment target is 50 participants, below the 665-participant average among 105 other Cognitive Impairment trials with a reported enrollment target (92% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05500170, a NA study of Cognitive Impairment and Sleep Quality, is actively recruiting participants, sponsored by State University of New York at Buffalo.
- RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 3
- Study locations
Study Summary
Poor sleep quality and short sleep duration may be a mechanistic component of cognitive impairment in older adults, associated with a decline in brain-derived neurotrophic factor. Increasing the availability of nicotinamide adenine dinucleotide (NAD+) with supplementation of its precursor, nicotinamide riboside (NR), a form of vitamin B3 may increase the expression of brain-derived neurotrophic factor. This study proposes to examine the benefits of NR supplementation on sleep and cognitive function in older adults with comprehensive subjective and objective measures and to explore its impacts on serum brain-derived neurotrophic factor.
Primary Outcome
Sleep quality will be assessed with the Pittsburgh Sleep Quality Index , where global score \>5 indicates poor sleep quality and global score \<5 indicates good sleep quality.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Nicotinamide riboside
Study Locations (3)
New York
- State University of New York at Buffalo - Buffalo
- University at Buffalo State University of New York - Buffalo
- Buffalo Veteran Affairs Medical Center - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-04-04 |
| Est. Completion | 2027-08-30 |
| Phase | NA |
What NCT05500170 shows while recruiting
NCT05500170 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 665-participant average among 105 other Cognitive Impairment trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Cognitive Impairment appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05500170 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05500170 about?
NCT05500170 is a clinical study titled "Benefits of Nicotinamide Riboside Upon Cognition and Sleep". Poor sleep quality and short sleep duration may be a mechanistic component of cognitive impairment in older adults, associated with a decline in brain-derived neurotrophic factor. Increasing the availability of nicotinamide adenine dinucleotide (NAD+) with supplementation of its precursor, nicotinam...
What is the current status of trial NCT05500170?
This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2023-04-04. Estimated completion is 2027-08-30.
What conditions does trial NCT05500170 study?
This clinical trial studies the following conditions: Cognitive Impairment, Sleep Quality.
What interventions are being tested in trial NCT05500170?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Nicotinamide riboside (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05500170?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05500170 being conducted?
This trial has 3 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cognitive Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05500170's enrollment target sits among peer trials
50 71st of 105 higher than 33 of 105 other Cognitive Impairment trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cognitive Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Investigating the Effects of Wearable Robotic Exoskeleton for Improving Mobility and Cognition in Persons With MS
RECRUITING · NA
-
Mind Your Heart-II
RECRUITING · NA
-
Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke
RECRUITING · NA
-
Impact of a Multimodal Lifestyle Intervention on Dementia Risk Factors and Attitude Related to Dementia Risk: A Logistical Pilot Study
RECRUITING · NA
-
Essential Fats For Enhancing Cognitive Thinking (EFFECT) Study
RECRUITING · NA
-
Amygdala Memory Enhancement
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI